Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMEPAN trial of immediate versus delayed chemotherapy for asymptomatic metastatic pancreatic cancer
NL-OMON59492Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Quality Adjusted Overall Survival. Started Oct 2024; status: recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59492.